AN ISO 9001 & A WHO GMP CERTIFIED COMPANY

M/s. Ortin Laboratories Limited
D.No: 1-2-593/29, Ground Floor,
Street No. 4, Gagan Mahal Colony,
Domalguda, Hyderabad - 500 029.
Telangana, India.

Ortin LABORATORIES LTD

Date: 11.02.2016

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051,

Sub: Outcome of Board Meeting held on 11.02.2016.

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s Ortin Laboratories Ltd. held on Thursday, 11.02.2016 at 4.00 P.M the following were duly considered and approved:

1. Unaudited financial results for the quarter ended 31.12.2015. (Attached in Annexure I)

2. Limited Review Report for the quarter ended 31.12.2015. (Attached in Annexure II)

3. Appointment of secretarial auditor for the financial year 2015-16.

4. The Board has considered the proposal and decided to start OTC Marketing of Products like Cough Syrup, Pain cream, Pain Spray, Pain tablets, Anti Cold tablets all over India which will yield good revenue in coming years.

5. The Board Noted and ratified the Agreement and under this, the Company in Collaboration with M/s. GDH Workforce Private Limited submit the proposal to the Ministry of Rural Development, Government of India in response to the scheme namely Aajeevika Skills- (DDUGKY Guidelines) ("Scheme") formulated for providing skill development training to public at large in various states across India.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Ortin Laboratories Limited.

S. Murali Krishna Murthy
Managing Director
(DIN: 00540632)

Encl: As Above

M/s. Ortin Laboratories Limited
D.No. 1-2-593/29, Ground Floor,
Street No. 4, Gagan Mahal Colony,
Domalguda, Hyderabad - 500 029.
Telangana, India.

AN ISO 9001 & A WHO GMP CERTIFIED COMPANY

Ortin LABORATORIES LTD

ORTIN LABORATORIES LIMITED

STATEMENT FOR UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2015

(Rs. In Lakhs)

S. No	Particulars	Three months ended	Preceeding Three months ended	Correspondin gThree months ended	9 months ended	9 months ended	Previous Year ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	869.25	686.18	481.44	2255.25	2222.46	3924.32
	(b) Other operating income	479.93	615.84	495.97	1624.12	1522.08	2116.94
	Total income from operations (net)	1349.18	1302.02	977.41	3879.38	3744.54	6041.26
2	Expenses						
	(a) Cost of materials consumed	120.57	1429.51	349.06	2264.60	2137.96	4185.17
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	722.44	-721.20	135.99	24.18	129.80	-13.22
	(d) Employee benefits expense	74.16	64.09	60.97	201.51	177.20	241.07
	(e) Depreciation and amortisation expense	42.38	40.99	63.47	123.89	114.76	164.15
	(f) Other expenses(Any item exceeding 10% of total expenses relating to continuing operations to be shown seperately)(includes rates and taxes)	306.72	300.41	241.14	858.46	733.39	978.59
	Total expenses	1266.27	1113.79	850.62	3472.64	3293.11	5555.76
3	Profit / (Loss) from operations before other income, finance costs and exceptional items(1-2)	82.91	188.23	126.79	406.74	451.42	485.50
4	Other income	9.03	3.75	1.24	18.62	19.64	22.02
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	91.93	191.98	128.03	425.35	471.06	507.51
6	Finance costs	86.10	95.09	86.93	248.09	269.81	352.15
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	5.83	96.89	41.10	177.27	201.25	155.37
8	Exceptional items	0.97	-0.10	-22.10	0.87	-22.10	-22.03
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	6.81	96.79	19.01	178.14	179.15	133.33
10	Tax expense	-5.50	32.62	13.45	52.36	65.55	43.54
11	Net profit or loss from ordinary activities after tax(9+/-10)	12.30	64.17	5.55	125.77	113.60	89.79
12	Extraordinary items (net of tax expense Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	12.30	64.17	5.55	125.77	113.60	89.79
14	Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	12.30	64.17	5.55	125.77	113.60	89.79
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1694.04	1694.04	1694.04	1694.04	1694.04	1694.04

M/s. Ortin Laboratories Limited
D.No. 1-2-593/29, Ground Floor,
Street No. 4, Gagan Mahal Colony,
Domalguda, Hyderabad - 500 029.
Telangana, India.

AN ISO 9001 & A WHO GMP CERTIFIED COMPANY

18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	549.83	549.83	502.16	549.83	502.16	549.83
19.i.	Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):						
	(a) Basic	0.07	0.38	0.03	0.74	0.67	0.53
	(b) Diluted	0.07	0.38	0.03	0.74	0.67	0.53
19.ii.	Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):						
	(a) Basic	0.07	0.38	0.03	0.74	0.67	0.53
	(b) Diluted	0.07	0.38	0.03	0.74	0.67	0.53

ORTIN LABORATORIES LIMITED

STATEMENT FOR UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2015

S. No	Particulars	Three months ended	Preceeding Three months ended	CorrespondingThree months ended	9 months ended	9 months ended	Previous Year ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	i. Number of shares	10840120	10361015	10174039	10840120	10174039	10174039
	ii.Percentage of Shareholding	63.99%	61.16%	60.06%	63.99%	60.06%	60.06%
2	Promoters and Promoter Group Shareholding **						
	a) Pledged / Encumbered						
	i. Number of shares	0	0	0	0	0	0
	ii.Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0	0	0
	iii.Percentage of shares (as a % of the total share capital of the company)	0	0	0	0	0	0
	b) Non - encumbered						
	i. Number of shares	6100280	6579385	6766361	6100280	6766361	6766361
	ii.Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	iii.Percentage of shares (as a % of the total share capital of the company)	36.01%	38.84%	39.94%	36.01%	39.94%	39.94%

	Particulars	Three months ended 31.12.2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

NOTE: 1) The above results have been taken on record by the Board of directors at their meeting held on 11/02/2016

PLACE: HYDERABAD,
DATE: 11-02-2016

For ORTIN LABORATORIES LIMITED

S.MURALI KRISHNA MURTHY
MANAGING DIRECTOR

Corp. & Regd. Office : [redacted] (T.S.) India. Phone : +91-40-27562055 / +91-40-27567266 / Fax : +91-40-66103055
Website : www.ortinlabsindia.com Email : info@ortinlabsindia.com
CIN: L24110TG1986PLC006885

MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Review Report to the Board of Directors of **ORTIN LABORATORIES LIMITED**

1. We have reviewed the statement of unaudited financial results (The "Statement") of **Ortin Laboratories Limited** (The "Company") for the quarter ended December 31st, 2015 including the statement of assets and liabilities as on that date. The Statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"), which has been initialed by us for identification purposes. The Statement is the responsibility of Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement.

3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of Companies Act 2013 read with Rule 7 of Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, and has not disclosed information required to be disclosed in terms of Regulation 33 of Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

MATHESH & RAMANA ★ FRN:002020S ★ HYDERABAD ★ CHARTERED ACCOUNTANTS

B. V. RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad
Date: 11/02/2016

E-mail : mateshca@yahoo.co.in
3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 Fax: 2322 2863

AN ISO 9001 & A WHO GMP CERTIFIED COMPANY

M/s. Ortin Laboratories Limited
D.No: 1-2-593/29, Ground Floor,
Street No. 4, Gagan Mahal Colony,
Domalguda, Hyderabad - 500 029.
Telangana, India.

Ortin LABORATORIES LTD

Date: 11.02.2016

To,

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051,

Sub: Regulation 30 Disclosure of Price-Sensitive Information.

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of M/s Ortin Laboratories Ltd. held on Thursday, 11.02.2016 at 4.00 P.M the Board considered following:

(1) The Board has considered the proposal and decided to start OTC Marketing of Products like Cough Syrup, Pain cream, Pain Spray, Pain tablets, Anti Cold tablets all over India which will yield good revenue in coming years.

(2) The Board Noted and ratified the Agreement and under this, the Company in Collaboration with M/s. GDH Workforce Private Limited submit the proposal to the Ministry of Rural Development, Government of India in response to the scheme namely Aajeevika Skills- (DDUGKY Guidelines) ("Scheme") formulated for providing skill development training to public at large in various states across India.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Ortin Laboratories Limited

S. Murali Krishna Murthy
Managing Director
(DIN: 00540632)

Encl: As Above